Alpelisib (Standard)

Alpelisib (Standard) is the analytical standard of Alpelisib. This product is intended for research and analytical applications. Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity[1][2][3].

Product Specifications

CAS Number

[1217486-61-7]

UNSPSC

12352100

Hazard Statement

H302, H315, H319, H335

Target

PI3K; Reference Standards

Related Pathways

Others; PI3K/Akt/mTOR

Field of Research

Cancer

Purity

99.86

Smiles

CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3

Molecular Formula

C19H22F3N5O2S

Molecular Weight

441.47

Precautions

H302, H315, H319, H335

References & Citations

[1]Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013 Jul 1;23 (13) :3741-8.|[2]Fritsch C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014 May;13 (5) :1117-29.|[3]Gobin B, et al. BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer. 2015 Feb 15;136 (4) :784-96.